Fusioner: Kommissionen giver afkald på de tilsagn, som Takeda gav for at få godkendt sit køb af Shire
(WorldNews Health)

The European Commission has waived, under the EU Merger Regulation, the commitments made by Takeda to obtain clearance of its acquisition of Shire. The Commission approved the acquisition of Shire by Takeda on 20 November 2018, subject to the divestment of a biologic drug under development by Shire to treat inflammatory bowel diseases (`IBD`), namely SHP 647. IBD is a lifelong autoimmune disease that involve inflammation of the digestive tract. Biologic drugs are typically prescribed after the failure of conventional therapies, such as corticosteroids and immunosuppressants. The Commission`s investigation Following a number of...